These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Adjuvant therapy for breast cancer. NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506 [TBL] [Abstract][Full Text] [Related]
3. [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients]. Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J Cancer Radiother; 2004 Jun; 8(3):155-67. PubMed ID: 15217583 [TBL] [Abstract][Full Text] [Related]
4. A cost-effectiveness analysis of axillary node dissection in postmenopausal women with estrogen receptor-positive breast cancer and clinically negative axillary nodes. Orr RK; Col NF; Kuntz KM Surgery; 1999 Sep; 126(3):568-76. PubMed ID: 10486611 [TBL] [Abstract][Full Text] [Related]
6. [Studies with high-dose chemotherapy and subsequent autologous stem cell transplantation in breast carcinoma]. Nitz U; Adomeit A; Mohrmann S; Fossari A; Frick M Praxis (Bern 1994); 1998 Apr; 87(17):578-83. PubMed ID: 9623324 [TBL] [Abstract][Full Text] [Related]
7. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. National Institutes of Health Consensus Development Panel J Natl Cancer Inst Monogr; 2001; (30):5-15. PubMed ID: 11773285 [TBL] [Abstract][Full Text] [Related]
8. The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study. Montero AJ; Rouzier R; Lluch A; Theriault RL; Buzdar AU; Delaloge S; Bermejo B; Le M; Kau SW; Dunant A; Arriagada R; Spielmann M; Garcia-Conde J; Sahin AA; Singletary SE; Hortobagyi GN; Valero V Cancer; 2005 Jul; 104(2):229-35. PubMed ID: 15937910 [TBL] [Abstract][Full Text] [Related]
9. Breast cancer concepts. Hatfield HA; Guthrie TH Am Fam Physician; 1984 Aug; 30(2):195-200. PubMed ID: 6464959 [TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of the immunocytochemical detection of contaminating tumor cells (CTC) in apheresis products of patients with high-risk breast cancer treated with high-dose chemotherapy and stem cell transplantation. Solano C; Badia B; Lluch A; Marugan I; Benet I; Arbona C; Prosper F; García-Conde J Bone Marrow Transplant; 2001 Feb; 27(3):287-93. PubMed ID: 11277176 [TBL] [Abstract][Full Text] [Related]
11. A decision analysis of the effect of avoiding axillary lymph node dissection in low risk women with invasive breast carcinoma. Jackson JS; Olivotto IA; Wai M D E; Grau C; Mates D; Ragaz J Cancer; 2000 Apr; 88(8):1852-62. PubMed ID: 10760762 [TBL] [Abstract][Full Text] [Related]
12. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy. Kim KJ; Huh SJ; Yang JH; Park W; Nam SJ; Kim JH; Lee JH; Kang SS; Lee JE; Kang MK; Park YJ; Nam HR Jpn J Clin Oncol; 2005 Mar; 35(3):126-33. PubMed ID: 15741302 [TBL] [Abstract][Full Text] [Related]
13. Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients. Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1062-73. PubMed ID: 15234040 [TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929 [TBL] [Abstract][Full Text] [Related]
15. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. Taghian AG; Jeong JH; Mamounas EP; Parda DS; Deutsch M; Costantino JP; Wolmark N J Clin Oncol; 2006 Aug; 24(24):3927-32. PubMed ID: 16921044 [TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer. Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997 [TBL] [Abstract][Full Text] [Related]
17. Management of locally advanced and inflammatory carcinoma of the breast. Ackland SP; Bitran JD; Dowlatshahi K Surg Gynecol Obstet; 1985 Oct; 161(4):399-408. PubMed ID: 3901356 [TBL] [Abstract][Full Text] [Related]
18. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973 [TBL] [Abstract][Full Text] [Related]
19. Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast. Botti C; Vici P; Lopez M; Scinto AF; Cognetti F; Cavaliere R J Am Coll Surg; 1995 Sep; 181(3):202-8. PubMed ID: 7670678 [TBL] [Abstract][Full Text] [Related]
20. The role of chemotherapy for node-negative breast cancer. Cooper MR Cancer; 1991 Mar; 67(6 Suppl):1744-7. PubMed ID: 2001570 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]